These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2150 related items for PubMed ID: 24139829

  • 1. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA, Casale TB, Nelson HS, Demoly P.
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [Abstract] [Full Text] [Related]

  • 2. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, Bahceciler NN, Barlan IB.
    J Investig Allergol Clin Immunol; 2015 Sep; 25(5):334-42. PubMed ID: 26727762
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB.
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [Abstract] [Full Text] [Related]

  • 5. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB.
    Int Arch Allergy Immunol; 2012 Jun; 157(3):288-98. PubMed ID: 22041501
    [Abstract] [Full Text] [Related]

  • 6. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, Hering T, Huttegger I, Jung K, Klimek L, Kopp MV, Merk H, Rabe U, Saloga J, Schmid-Grendelmeier P, Schuster A, Schwerk N, Sitter H, Umpfenbach U, Wedi B, Wöhrl S, Worm M, Kleine-Tebbe J, Kaul S, Schwalfenberg A.
    Allergo J Int; 2014 Jun; 23(8):282-319. PubMed ID: 26120539
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy for house-dust mite allergy.
    Nelson HS.
    Allergy Asthma Proc; 2018 Jul 01; 39(4):264-272. PubMed ID: 30095391
    [Abstract] [Full Text] [Related]

  • 8. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C.
    Pediatr Allergy Immunol; 2007 Feb 01; 18(1):47-57. PubMed ID: 17295799
    [Abstract] [Full Text] [Related]

  • 9. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW.
    J Allergy Clin Immunol; 2014 Sep 01; 134(3):568-575.e7. PubMed ID: 24797423
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.
    J Allergy Clin Immunol; 2016 Dec 01; 138(6):1631-1638. PubMed ID: 27521719
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.
    Compalati E, Passalacqua G, Bonini M, Canonica GW.
    Allergy; 2009 Nov 01; 64(11):1570-9. PubMed ID: 19796205
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW, Virchow JC, Zieglmayer P, Ljørring C, Smith IM, Mosbech H.
    Expert Rev Clin Immunol; 2016 Aug 01; 12(8):805-15. PubMed ID: 27322777
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH, Xu C, Liu L, Chai RN.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun 06; 56(6):774-783. PubMed ID: 35785859
    [Abstract] [Full Text] [Related]

  • 14. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP.
    J Allergy Clin Immunol; 2013 Aug 06; 132(2):353-60.e2. PubMed ID: 23651609
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.
    JAMA; 2016 Apr 26; 315(16):1715-25. PubMed ID: 27115376
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D, Konno A.
    J Allergy Clin Immunol; 2017 Jun 26; 139(6):1840-1848.e10. PubMed ID: 27864024
    [Abstract] [Full Text] [Related]

  • 17. Update on house dust mite immunotherapy: are more studies needed?
    Nelson HS.
    Curr Opin Allergy Clin Immunol; 2014 Dec 26; 14(6):542-8. PubMed ID: 25115684
    [Abstract] [Full Text] [Related]

  • 18. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J.
    J Allergy Clin Immunol; 2016 Feb 26; 137(2):444-451.e8. PubMed ID: 26292778
    [Abstract] [Full Text] [Related]

  • 19. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO, Calderon MA, Durham SR.
    Expert Opin Biol Ther; 2013 Nov 26; 13(11):1543-56. PubMed ID: 24099116
    [Abstract] [Full Text] [Related]

  • 20. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR, Stumpf JL.
    Ann Pharmacother; 2018 Oct 26; 52(10):1019-1030. PubMed ID: 29642713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 108.